555 related articles for article (PubMed ID: 25512523)
1. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
[TBL] [Abstract][Full Text] [Related]
2. P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.
Song R; Tian K; Wang W; Wang L
Int J Surg; 2015 Aug; 20():80-7. PubMed ID: 25936826
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
[TBL] [Abstract][Full Text] [Related]
4. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review).
Hu K; Dai HB; Qiu ZL
Oncol Rep; 2016 Sep; 36(3):1219-25. PubMed ID: 27430283
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
[TBL] [Abstract][Full Text] [Related]
6. Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway.
Yuan B; Shi K; Zha J; Cai Y; Gu Y; Huang K; Yue W; Zhai Q; Ding N; Ren W; He W; Xu Y; Wang T
Cell Death Dis; 2023 Jan; 14(1):51. PubMed ID: 36681687
[TBL] [Abstract][Full Text] [Related]
7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D
Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720
[TBL] [Abstract][Full Text] [Related]
8. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.
Gupte A; Baker EK; Wan SS; Stewart E; Loh A; Shelat AA; Gould CM; Chalk AM; Taylor S; Lackovic K; Karlström Å; Mutsaers AJ; Desai J; Madhamshettiwar PB; Zannettino AC; Burns C; Huang DC; Dyer MA; Simpson KJ; Walkley CR
Clin Cancer Res; 2015 Jul; 21(14):3216-29. PubMed ID: 25862761
[TBL] [Abstract][Full Text] [Related]
9. Targeting osteosarcoma.
Reed DE; Shokat KM
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18100-1. PubMed ID: 25512494
[No Abstract] [Full Text] [Related]
10. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms and microRNAs in Osteosarcoma Pathogenesis.
Kushlinskii NE; Fridman MV; Braga EA
Biochemistry (Mosc); 2016 Apr; 81(4):315-28. PubMed ID: 27293089
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
[TBL] [Abstract][Full Text] [Related]
13. Aplasia Ras homologue member Ⅰ overexpression inhibits tumor growth and induces apoptosis through inhibition of PI3K/Akt survival pathways in human osteosarcoma MG-63 cells in culture.
Ye K; Wang S; Yang Y; Kang X; Wang J; Han H
Int J Mol Med; 2015 Sep; 36(3):776-82. PubMed ID: 26165148
[TBL] [Abstract][Full Text] [Related]
14. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells.
Geng YD; Yang L; Zhang C; Kong LY
Food Chem Toxicol; 2014 Nov; 73():7-16. PubMed ID: 25119583
[TBL] [Abstract][Full Text] [Related]
15. RASSF5 inhibits growth and invasion and induces apoptosis in osteosarcoma cells through activation of MST1/LATS1 signaling.
Zhou XH; Yang CQ; Zhang CL; Gao Y; Yuan HB; Wang C
Oncol Rep; 2014 Oct; 32(4):1505-12. PubMed ID: 25109282
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
17. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
[TBL] [Abstract][Full Text] [Related]
18. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways.
Miwa S; Sugimoto N; Yamamoto N; Shirai T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Igarashi K; Yachie A; Tsuchiya H
Anticancer Res; 2012 Sep; 32(9):3643-9. PubMed ID: 22993301
[TBL] [Abstract][Full Text] [Related]
19. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
Choy E; Hornicek F; MacConaill L; Harmon D; Tariq Z; Garraway L; Duan Z
Cancer; 2012 Jun; 118(11):2905-14. PubMed ID: 22006429
[TBL] [Abstract][Full Text] [Related]
20. PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway.
Tang HY; Guo JQ; Sang BT; Cheng JN; Wu XM
Biochem Cell Biol; 2022 Feb; 100(1):75-84. PubMed ID: 34678088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
